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OBJECTIVES: Crohn’s disease is a chronic relapsing-remitting inflammatory bowel
disease with heterogeneous disease course, requiring life-long treatment. Pheno-
types explaining disease heterogeneity is of interest in optimizing allocation of
health care resources, e.g. to avoid expensive maintenance treatment to prolong
remission in patients who seldom relapse. To develop economic models for eval-
uation of treatments, our objective was to estimate parameters of a Markov chain
from data on disease activity and resource consumption and to improve model fit
by allowing different phenotypes. METHODS: We had individual data on relapse
and remission, surgery, use of medicines and other resources, aggregated over
three month periods, from inflammatory bowel disease patients from 1991 and ten
year onwards. Data from Crohn’s disease patients were extracted. An exact maxi-
mum likelihood estimator using observations aggregated over time was used to
estimate monthly transition probabilities. This estimator was adjusted to allow
different disease phenotypes using an Expectation-Maximization method which
identifies the phenotypes that best describe patient heterogeneity. The estimated
parameters were used to derive the mean durations of a relapse and a period of
remission to describe the phenotypes. RESULTS: At least two distinct phenotypes
were found in each country, seldom-relapsing (once/3 years) and often-relapsing
(once/3 years). The best fit was with four phenotypes in Denmark, three pheno-
types in the Netherlands and in Italy, and two in Norway, Israel, Ireland, Spain, and
Greece. In Denmark and Italy there was a single seldom-relapsing phenotype and
more than one often-relapsing phenotype. In Netherlands there was two seldom-
relapsing phenotypes. Denmark, The Netherlands, Israel, Ireland and Italy have
roughly as many seldom-relapsing as often-relapsing patients. Norway, Spain and
Greece have a majority of seldom-relapsing patients. CONCLUSIONS: Allowing for
different phenotypes improves model fit. Health care resource allocation can be
optimized using phenotypes. Using data aggregated over time appears to remain a
challenge.
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OBJECTIVES: The Swedish National Diabetes Register (NDR) has since 1996 longi-
tudinally recorded medical outcomes e.g. risk factors, comorbidities, and covers
the majority (80%) of Swedish diabetes patients. In addition patient reported values
were collected alongside the registry in a questionnaire. Our purpose was to eval-
uate a method for measuring patient reported abilities and ratings of quality in
health care and evaluating them together with outcomes extracted from the NDR.
METHODS:A questionnaire was developed to measure if diabetes care is percieved
as patient focused and efficient, through questions on self management ability,
worries, ability to carry out daily acitivites, and perception of service, access and
involvement. The questionnaire was issued to 4,760 patients, 2,916 responded.
Registry data on risk factors (HbA1c, blood pressure, cholesterol) were extracted for
each patient and connected to the questionnaire. Item Response Theory (IRT) was
used to estimate patient abilities and patient ratings of quality in health care (IRT
scores) from the response patterns. For each patient, registry data and IRT scores
were used to derive an overall Malmquist approach output quantity index, a health
care related component and a patient ability component. The index is a measure-
ment of how efficiently the patient leads his or her life with diabetes and its care,
and provides a measure of the patient’s state of health in relation to the patient’s
situation. RESULTS: We obtained IRT scale models with good fit, satisfactory vali-
dated in another population. The IRT scores provide basis for patient evaluation in
a broader perspective than risk factors alone. The ability index component varies
more than the health care component.CONCLUSIONS:The questionnaire provides
estimates of abilities and ratings of quality. Our approach allows estimating patient
benefit and health care production using combined registry and patient reported
data, the procedure probably easier for patients than methods like time trade-off.
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OBJECTIVES: liraglutide and exenatide are the two known approved GLP-1 ana-
logue drug in the management of diabetes, a network meta-analysis was per-
formed to get a more robust evidence on the efficacy of liraglutide compared to
exenatide in achieving HbA1c  7.0% in more diabetic patient. METHODS: Elec-
tronic database was browsed for available material on the proposed subject until
May 2012, the inclusion criteria were phase 3 randomise controlled trials in diabe-
tes type 2 patients. The software ADDIS 1.14 (Aggregate Data Drug Information
System) was used to perform the network meta-analysis of liraglutide, exenatide
and insulin glargin. RESULTS: Node-splitting analyses showed that were no rele-
vant inconsistency in the evidence. A consistency model was used to draw conclu-
sion about the relative effect of the three treatments. The relative risk (RR) of
liraglutide compared to exenatide is 1.28 (0.57, 2.82), RR of liraglutide compared to
insulin glargine is 1.72 (0.70, 4.37) and the RR of exenatide compared to insulin
glargine is 1.35 (0.66, 2.76). A vague prior for the study specific baseline () and the
treatment effect coefficients () are   N (0, 3.563E-3) and   N (0, 3.563E-3)
respectively. The rank probability of the three drugs ranked liraglutide first, ex-
enatide second and insulin glargine as the last in rank of the best treatments.
CONCLUSIONS: Liraglutide is still effective in maintaining the HbA1c  7.0% in
more diabetes patients compared to exenatide and insulin glargine however ex-
enatide once weekly seems to be more convenient to administer and has a cost
advantage compared to liraglutide once daily dose. Liraglutide dose may need to be
modified to once weekly or once monthly dose to me more effective in the man-
agement of diabetes type 2.
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OBJECTIVES: Planning and designing patient registries requires significant re-
search to determine the type and amount of data to collect, identifying recruitment
sites, understanding the impact of study criteria on sample size, and estimating
patient retention. Our objective was to test the utility of a new tool for answering
these questions in a timely and cost-efficient manner, and to examine how claims
data can be leveraged to plan registry design. METHODS: We used an online inter-
active data analysis tool, MarketScan®Treatment Pathways, to explore the character-
istics and health care utilization patterns in a sample of cancer patients with pain.
Patients newly diagnosed with prevalent cancers that are highly associated with
pain such as multiple myeloma, colorectal, lung, prostate, or breast cancer were
included, if they had at least 2 ICD-9 codes for one of the cancers on different days
within 60 days of each other. A 6-month pre-period without any cancer diagnosis
was used to identify new cancer patients. RESULTS: Of the 365,980 cancer patients
meeting the entry criteria, 54% had an ICD-9 code for pain-related diagnosis. The
median and mean number of days from cancer to pain diagnosis was 113 and 192
days, respectively. Only 3% had a co-morbidity that would exclude participation in
the registry. Nearly 64% patients had an outpatient office visit within 30-days, of
them, 68% had a subsequent visit in the following 30-days. Patient diagnoses,
medications and procedures were described for the 60-day period following cancer
pain diagnosis. The full analysis took 6 hours including all iterations on study
criteria, and outputting descriptive data on patient demographic and clinical
characteristics. CONCLUSIONS: Using MarketScan®Treatment Pathways, we tested
sample selection criteria and health care utilization in a fraction of time than
typical database analyses. These data answered critical questions in the study
design for a planned cancer pain registry in a timely and cost-efficient way.
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OBJECTIVES: A systematic literature review (SLR) is a well-established tool for
identifying and assimilating existing evidence or identifying gaps that need to be
filled by new research. Although SLRs are widely used in the drug reimbursement
sphere, there are many challenges in maximizing its value and in communicating
project objectives with a vendor. The objective of this study is to outline the deliv-
erables of a SLR, and examine the optimal methodology in extracting maximum
value from a SLR review by exploring important caveats and pitfalls of two hypo-
thetical case studies. METHODS: Two hypothetical case studies are used to outline
the process and the pitfalls of a SLR project and the relationship between industry
and vendor. Feedback was elicited from consultants and industry in order to iden-
tify expectations and advice for a successful systematic literature review.
RESULTS: The analysis found that in depth discussion during the protocol phase of
the SLR is crucial to the success of the project. A successful protocol will incorpo-
rate: key questions that are focused and specific, scoping to outline the search
strategy, and address the purpose of the review in terms of a product’s value story
(ie. a SLR for inclusion in a GVD), or evidence development. The analysis found that
some challenges include too much or too little literature, which can be due to a very
broad or narrow research question, challenges that arise due to expectations for
certain data, and addressing gaps in the literature. Several suggestions on over-
coming these challenges and caveats of the methodology are explored through the
hypothetical case studies. CONCLUSIONS: The authors found that communication
and a focused question were the most helpful in yielding successful literature
reviews. Furthermore, detailed discussion at the protocol stage helped to avoid
pitfalls at later points in SLR development. The authors provide a list of pitfalls and
remedies that may help when considering SLRs.
RESEARCH ON METHODS - Modeling Methods
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OBJECTIVES: In the absence of long-term randomized clinical trials (RCTs) on the
effectiveness of pharmacological treatment for primary cardiovascular disease
(CVD) prevention, risk prediction models are used to project changes in CVD inci-
dence due to changes on risk factor levels observed in short-term RCTs. This study
aims to summarize the literature on the application of these CVD risk models in
pharmacoeconomic studies for primary CVD prevention interventions in high in-
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